Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | MicrobiomeTrials← Back to trialsNCT03786783
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2019-03-04Est. Completion: 2021-12-31
Enrollment target: 42 participants Locations- Children's Hospital Los Angeles, Los Angeles, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
- Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
- Primary Children's Hospital, Salt Lake City, Utah, United States
- The Children's Hospital at Westmead, Westmead, New South Wales, Australia
- Royal Children's Hospital, Parkville, Victoria, Australia
- Starship Children's Hospital, Grafton, Auckland, New Zealand
Other microbiome trials you might be interested in
Ganglioneuroblastoma, NodularNeuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care su…
Birmingham, United StatesEst. completion Dec 31, 2029
NeuroblastomaGanglioneuroblastoma
Patients with recurrent or refractory neuroblastoma are resistance to conventional chemotherapy. For this reason, the in…
Seattle, United StatesEst. completion Nov 2023